All News
Secukinumab Shows Efficacy in Two Ankylosing Spondylitis Trials
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis.
Read ArticleTofacitinib Shows Promise in Alopecia, Eczema and Vitiligo
Tofacitinib has been approved for use in rheumatoid arthritis.
Read Article2015 ACR RA Guidelines Released– Finally! (Best of 2015: #2)
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
Read ArticleThe History of Citrullination (Best of 2015)
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
Read ArticleHow I Choose Biologics (Best of 2015)
Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.
Read ArticlePreventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments (Best of 2015)
Reactivation of hepatitis B virus infection can have devastating consequences, especially amongst those patients receiving immunosuppressive therapy.
Read ArticleDAS28-CRP or DAS28-ESR: Are they Biosimilar? (Best of 2015)
The disease activity score (DAS28) has been developed as a dynamic assessment tool and a therapeutic response measure for use in clinical trials and practice.
Read ArticleWill the Balance of JAK inhibition Yield Better Outcomes? Results of New JAK inhibitor - Peficitinib
Researchers from Keio University have published their results using novel JAK inhibitor peficitinib (ASP015K) as a monotherapy in moderate to severe RA patients.
Read ArticleHerpes Zoster Increases the Risk of Stroke and MI
At the 2015 ACR annual meeting in San Francisco, Len Calabrese, DO, of the Cleveland Clinic, gave a plenary session talk linking "shingles" infection to an increased risk of CVA (
Read ArticlePlasmacytoid Dendritic Cells Influences Early, But Not Established Lupus
The Journal of Immunology has published the findings of Virginia Tech researchers who have studied plasmacytoid dendritic cells and their ability to induce type I alpha interferon (IFN-α) in lupus. (Citation source: http://buff.ly/1MceeCl)
Read ArticleRA Guidelines, Methotrexate and Mortal Risks in Gout: November 2015 top social media news
Here's what you may have missed: in November 2015, RheumNow published 80 tweets on news, research and teaching points that impact the rheumatology community. We had a reach (impressions) of 79,100, 79 mentions, and over 3399 visits to RheumNow.com to check out what we publish.
Read ArticleTwo-Fold Increase of Demyelinating Diseases with TNF Inhibition
Despite the potential contributory role of TNF in the pathogenesis of multiple sclerosis, several trials have shown that TNF inhibitor (TNFi) use may lead to worsening of MS, optic neuritis and other demyelinating disorders.
Read ArticleDRIVE Trial: Denosumab and Methotrexate Prevent Joint Erosions
Joint erosions in RA result from a complex process with multiple contributing mechanisms. One of those mechanisms involves RANK receptor activation by RANKL leading to osteoclast differentiation, activation and survival.
Read ArticleEULAR 2015 Psoriatic Arthritis Treatment Guidelines
The management of psoriatic disease, including psoriatic arthritis (PsA) has evolved significantly in the last decade. Nevertheless, there are still some uncertainties - such as what the role of methotrexate should be, and when to use newer and novel therapies.
Read ArticleRituximab's Efficacy May Be Correlated with CD4 T Cell Counts
Rituximab (RTX) is highly effective at B cell depletion and this may be one of several hypothetical ways in which the drug works. B cell numbers (measured as CD19+ B cells) plummet rapidly after the first infusion and stay down for 6-12 months.
Read ArticleThe Rising Price of Dermatologic Drugs
Containment of health care costs was a primary goal of the Patient Protection and Affordable Care Act. But there is little evidence of success in curbing the rising price of prescription drugs. As such, many medications are unaffordable to those who need them.
Read ArticleFertility in RA Linked to Disease Activity, NSAIDs and Prednisone
Brouwer and colleagues from the University Medical Center Rotterdam in The Netherlands have studied the issue of infertility in a cohort of RA patients followed prospectively.
Read ArticleEczema May Respond to Tofacitinib
A recent report from the Journal of the American Academy of Dermatology found that the oral Janus kinase (JAK) inhibitor tofacitinib to be effective in the treatment of moderate to severe atopic dermatitis.
Read ArticleDSB: ACR 2015 Safety Reports
The following is a compilation of abstracts presented at the 2015 Annual ACR meeting in San Francisco. These were chosen on the basis of impact, quality and safety message.
Read ArticleInterstitial Lung Disease Not Increased with Biologics
Extraarticular manifestations affect more then half of rheumatoid arthritis (RA) patients, and interstitial lung disease or "RA lung" is one of the more prevalent. The frequency of ILD in patients with RA varies from 5% to 58%.
Read Article